Drug Trial Radar · NCT03776812
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Apr 5, 2019
Primary completion
Mar 16, 2021
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Conditions
- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Interventions
RelacorilantDrug
Relacorilant is supplied as capsules for oral dosing.
Nab-paclitaxelDrug
Nab-paclitaxel is administered as IV infusion over 30-40 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Baseline and up to 15 months
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Site Reference ID/Investigator #004
Birmingham, Alabama
Site Reference ID/Investigator #038
Scottsdale, Arizona
Site Reference ID/Investigator #032
Denver, Colorado
Site Reference ID/Investigator #001
Chicago, Illinois
Site Reference ID/Investigator #106
Boston, Massachusetts
Site Reference ID/Investigator #128
Boston, Massachusetts
Site Reference ID/Investigator #051
New York, New York
Site Reference ID/Investigator #169
New York, New York
Site Reference ID/Investigator #170
New York, New York
Site Reference ID/Investigator #127
Pittsburgh, Pennsylvania
Site Reference ID/Investigator #135
Charlottesville, Virginia
Site Reference ID/Investigator #121
Milwaukee, Wisconsin
Site Reference ID/Investigator #109
Brussels, Belgium
Site Reference ID/Investigator #119
Edegem, Belgium
Site Reference ID/Investigator #108
Leuven, Belgium
Site Reference ID/Investigator #117
Toronto, Ontario, Canada
Site Reference ID/Investigator #096
Montreal, Quebec, Canada
Site Reference ID/Investigator #122
Milan, Italy
Site Reference ID/Investigator #112
Naples, Italy
Site Reference ID/Investigator #124
Roma, Italy
Site Reference ID/Investigator #115
Barcelona, Spain
Site Reference ID/Investigator #114
Madrid, Spain
Site Reference ID/Investigator #116
Madrid, Spain
Site Reference ID/Investigator #113
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.